Rituximab in Renal Allograft Recipients Who Develop Early De Novo Anti-HLA Alloantibodies

NCT00307125 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

757

Enrollment

NIH

Sponsor class

Conditions

Kidney Transplant
Kidney Transplant Recipient
Graft Function/Survival
de Novo HLA Antibodies Development

Interventions

DRUG: Rituximab plus immunosuppression
DRUG: Placebo plus immunosuppression

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)

Collaborators

[object Object]
[object Object]